Targeting cancer testis antigens in synovial sarcoma

Geoffrey Mitchell, Seth M. Pollack, Michael J. Wagner*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Synovial sarcoma (SS) is a rare cancer that disproportionately affects children and young adults. Cancer testis antigens (CTAs) are proteins that are expressed early in embryonic development, but generally not expressed in normal tissue. They are aberrantly expressed in many different cancer types and are an attractive therapeutic target for immunotherapies. CTAs are expressed at high levels in SS. This high level of CTA expression makes SS an ideal cancer for treatment strategies aimed at harnessing the immune system to recognize aberrant CTA expression and fight against the cancer. Pivotal clinical trials are now underway, with the potential to dramatically alter the landscape of SS management and treatment from current standards of care. In this review, we describe the rationale for targeting CTAs in SS with a focus on NY-ESO-1 and MAGE-A4, the current state of vaccine and T-cell receptor-based therapies, and consider emerging opportunities for future development.

Original languageEnglish (US)
Article numbere002072
JournalJournal for immunotherapy of cancer
Volume9
Issue number6
DOIs
StatePublished - Jun 3 2021

Keywords

  • biomarkers
  • immunotherapy
  • investigational
  • review
  • sarcoma
  • therapies
  • tumor

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting cancer testis antigens in synovial sarcoma'. Together they form a unique fingerprint.

Cite this